News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Exiqon Diagnostics, Inc. Announces BRAF Mutation Analysis for Predicting Therapeutic Response in Colorectal Cancer Patients



7/8/2009 8:37:02 AM

VEDBAEK, Denmark, July 8, 2009 (GLOBE NEWSWIRE) -- Exiqon announced today that it now offers BRAF Mutation Analysis through its CLIA laboratory in California. Cancer treating physicians now have access to this critical test for their advanced stage colorectal cancer patients who are candidates for anti-EGFR targeted therapy. A recent clinical study correlates the presence of BRAF mutations in colorectal cancer tumors with lack of patient response to cetuximab and panitumumab therapy.(1)

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES